Headlines about The Medicines (NASDAQ:MDCO) have been trending somewhat positive recently, Accern reports. The research group rates the sentiment of press coverage by analyzing more than twenty million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. The Medicines earned a news impact score of 0.05 on Accern’s scale. Accern also assigned news articles about the company an impact score of 45.8490765940745 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.
Here are some of the news articles that may have effected Accern’s rankings:
- Active-Investors: Blog Exposure – The Medicines Co. Completes Divestiture of Infectious Disease Business Unit to Melinta Therapeutics (finanznachrichten.de)
- Hospira (HSP) & The Medicines (MDCO) Critical Review (americanbankingnews.com)
- GenSight Biologics Receives MHRA Approval to Initiate Phase I/II PIONEER Clinical Trial of GS030 Gene Therapy in Retinitis Pigmentosa (markets.financialcontent.com)
- Mallinckrodt (MNK) to Sell Recothrom and Preveleak to Baxter (finance.yahoo.com)
- The Medicines Company Announces Closing of Divestiture of Infectious Disease Business Unit to Melinta Therapeutics (finance.yahoo.com)
A number of equities research analysts have weighed in on MDCO shares. Jefferies Group restated a “buy” rating and issued a $54.00 target price on shares of The Medicines in a research report on Thursday, September 14th. Chardan Capital reaffirmed a “buy” rating and issued a $85.00 price target on shares of The Medicines in a report on Wednesday, September 20th. Oppenheimer set a $50.00 price target on The Medicines and gave the company a “hold” rating in a report on Wednesday, October 4th. Zacks Investment Research cut The Medicines from a “hold” rating to a “strong sell” rating in a report on Tuesday, October 10th. Finally, Guggenheim started coverage on The Medicines in a report on Monday, October 23rd. They issued a “buy” rating and a $45.00 price target on the stock. One research analyst has rated the stock with a hold rating and ten have issued a buy rating to the company. The stock presently has an average rating of “Buy” and a consensus price target of $52.56.
The Medicines (NASDAQ:MDCO) last posted its quarterly earnings results on Wednesday, October 25th. The company reported ($0.42) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($1.37) by $0.95. The company had revenue of $16.87 million for the quarter, compared to analysts’ expectations of $26.06 million. The Medicines had a negative return on equity of 174.68% and a negative net margin of 767.94%. The firm’s revenue was down 55.1% on a year-over-year basis. During the same quarter in the prior year, the company earned ($0.64) earnings per share. equities research analysts forecast that The Medicines will post -8.86 EPS for the current fiscal year.
In other The Medicines news, CEO Clive Meanwell sold 136,250 shares of the business’s stock in a transaction on Friday, December 15th. The shares were sold at an average price of $27.24, for a total transaction of $3,711,450.00. Following the sale, the chief executive officer now directly owns 587,652 shares of the company’s stock, valued at approximately $16,007,640.48. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Director Alexander J. Denner bought 170,000 shares of the business’s stock in a transaction on Wednesday, November 29th. The shares were purchased at an average cost of $30.03 per share, for a total transaction of $5,105,100.00. Following the completion of the purchase, the director now owns 6,663 shares in the company, valued at $200,089.89. The disclosure for this purchase can be found here. 8.22% of the stock is currently owned by corporate insiders.
TRADEMARK VIOLATION NOTICE: This story was posted by Community Financial News and is the sole property of of Community Financial News. If you are accessing this story on another publication, it was copied illegally and republished in violation of U.S. & international trademark & copyright legislation. The legal version of this story can be accessed at https://www.com-unik.info/2018/01/11/somewhat-positive-media-coverage-somewhat-unlikely-to-affect-the-medicines-mdco-share-price.html.
About The Medicines
The Medicines Company is a global biopharmaceutical company. The Company is focused on advancing the treatment of acute and intensive care patients through the delivery of medicines to the hospital marketplace around the world. It markets Angiomax (bivalirudin), Ionsys (fentanyl iontophoretic transdermal system), Minocin (minocycline) for injection and Orbactiv (oritavancin).
Receive News & Ratings for The Medicines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for The Medicines and related companies with MarketBeat.com's FREE daily email newsletter.